477 related articles for article (PubMed ID: 25552580)
1. Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile.
Engevik MA; Engevik KA; Yacyshyn MB; Wang J; Hassett DJ; Darien B; Yacyshyn BR; Worrell RT
Am J Physiol Gastrointest Liver Physiol; 2015 Mar; 308(6):G497-509. PubMed ID: 25552580
[TBL] [Abstract][Full Text] [Related]
2. Human Clostridium difficile infection: altered mucus production and composition.
Engevik MA; Yacyshyn MB; Engevik KA; Wang J; Darien B; Hassett DJ; Yacyshyn BR; Worrell RT
Am J Physiol Gastrointest Liver Physiol; 2015 Mar; 308(6):G510-24. PubMed ID: 25552581
[TBL] [Abstract][Full Text] [Related]
3. Clostridium difficile toxins A and B decrease intestinal SLC26A3 protein expression.
Coffing H; Priyamvada S; Anbazhagan AN; Salibay C; Engevik M; Versalovic J; Yacyshyn MB; Yacyshyn B; Tyagi S; Saksena S; Gill RK; Alrefai WA; Dudeja PK
Am J Physiol Gastrointest Liver Physiol; 2018 Jul; 315(1):G43-G52. PubMed ID: 29597352
[TBL] [Abstract][Full Text] [Related]
4. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization.
Zhang L; Dong D; Jiang C; Li Z; Wang X; Peng Y
Anaerobe; 2015 Aug; 34():1-7. PubMed ID: 25817005
[TBL] [Abstract][Full Text] [Related]
5. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection.
Vincent C; Miller MA; Edens TJ; Mehrotra S; Dewar K; Manges AR
Microbiome; 2016 Mar; 4():12. PubMed ID: 26975510
[TBL] [Abstract][Full Text] [Related]
6. Loss of NHE3 alters gut microbiota composition and influences Bacteroides thetaiotaomicron growth.
Engevik MA; Aihara E; Montrose MH; Shull GE; Hassett DJ; Worrell RT
Am J Physiol Gastrointest Liver Physiol; 2013 Nov; 305(10):G697-711. PubMed ID: 24072680
[TBL] [Abstract][Full Text] [Related]
7. Bacillus amyloliquefaciens as prophylactic treatment for Clostridium difficile-associated disease in a mouse model.
Geeraerts S; Ducatelle R; Haesebrouck F; Van Immerseel F
J Gastroenterol Hepatol; 2015 Aug; 30(8):1275-80. PubMed ID: 25800047
[TBL] [Abstract][Full Text] [Related]
8. Increased intestinal permeability and downregulation of absorptive ion transporters
Peritore-Galve FC; Kaji I; Smith A; Walker LM; Shupe JA; Washington MK; Algood HMS; Dudeja PK; Goldenring JR; Lacy DB
Gut Microbes; 2023; 15(1):2225841. PubMed ID: 37350393
[TBL] [Abstract][Full Text] [Related]
9. [Investigation of toxin genes of Clostridium difficile strains isolated from hospitalized patients with diarrhoea at Marmara University Hospital].
Deniz U; Ulger N; Aksu B; Karavuş M; Söyletir G
Mikrobiyol Bul; 2011 Jan; 45(1):1-10. PubMed ID: 21341153
[TBL] [Abstract][Full Text] [Related]
10. Clostridium difficile and the disease it causes.
Norén T
Methods Mol Biol; 2010; 646():9-35. PubMed ID: 20597000
[TBL] [Abstract][Full Text] [Related]
11. Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth.
Weingarden AR; Dosa PI; DeWinter E; Steer CJ; Shaughnessy MK; Johnson JR; Khoruts A; Sadowsky MJ
PLoS One; 2016; 11(1):e0147210. PubMed ID: 26789728
[TBL] [Abstract][Full Text] [Related]
12. Impacts of infection with different toxigenic Clostridium difficile strains on faecal microbiota in children.
Ling Z; Liu X; Jia X; Cheng Y; Luo Y; Yuan L; Wang Y; Zhao C; Guo S; Li L; Xu X; Xiang C
Sci Rep; 2014 Dec; 4():7485. PubMed ID: 25501371
[TBL] [Abstract][Full Text] [Related]
13. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates.
Akerlund T; Svenungsson B; Lagergren A; Burman LG
J Clin Microbiol; 2006 Feb; 44(2):353-8. PubMed ID: 16455883
[TBL] [Abstract][Full Text] [Related]
14. Use of a Perianal Swab Compared With a Stool Sample to Detect Symptomatic Clostridium difficile Infection.
Montecalvo MA; Sisay E; McKenna D; Wang G; Visintainer P; Wormser GP
Infect Control Hosp Epidemiol; 2017 Jun; 38(6):658-662. PubMed ID: 28376944
[TBL] [Abstract][Full Text] [Related]
15. Clostridium difficile infection.
Kelly CP; LaMont JT
Annu Rev Med; 1998; 49():375-90. PubMed ID: 9509270
[TBL] [Abstract][Full Text] [Related]
16. Does Alkaline Colonic pH Predispose to Clostridium difficile Infection?
Gupta P; Yakubov S; Tin K; Zea D; Garankina O; Ghitan M; Chapnick EK; Homel P; Lin YS; Koegel MM
South Med J; 2016 Feb; 109(2):91-6. PubMed ID: 26840963
[TBL] [Abstract][Full Text] [Related]
17. Clostridium difficile infection aggravates colitis in interleukin 10-deficient mice.
Kim MN; Koh SJ; Kim JM; Im JP; Jung HC; Kim JS
World J Gastroenterol; 2014 Dec; 20(45):17084-91. PubMed ID: 25493020
[TBL] [Abstract][Full Text] [Related]
18. Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.
Lv Z; Peng G; Liu W; Xu H; Su J
Antimicrob Agents Chemother; 2015 Jul; 59(7):3726-35. PubMed ID: 25824219
[TBL] [Abstract][Full Text] [Related]
19. Fecal transplant for recurrent Clostridium difficile infection.
Lofland D; Josephat F; Partin S
Clin Lab Sci; 2013; 26(3):131-5. PubMed ID: 23967542
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis of intestinal epithelial cells restricts Clostridium difficile infection in a model of pseudomembranous colitis.
Saavedra PHV; Huang L; Ghazavi F; Kourula S; Vanden Berghe T; Takahashi N; Vandenabeele P; Lamkanfi M
Nat Commun; 2018 Nov; 9(1):4846. PubMed ID: 30451870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
